MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
Journal Article

Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys

2025
Request Book From Autostore and Choose the Collection Method
Overview
The Global Programme to Eliminate Lymphatic Filariasis has made significant gains through mass drug administration (MDA) of Ivermectin/Albendazole. Periodic evaluation of the MDA programme in lymphatic filariasis elimination is particularly useful in determining end points for stopping the programme. This is a follow-up study that sought to examine the effects of additional time and MDA intake on antigenemia seroreversion in persons who had previously tested positive for LF using the Filarial Test Strip (FTS) and the TropBio ELISA over a period of 1-5 years. A total of 542 individuals, from the Kassena Nankana East Municipal (N = 340) and Nabdam districts (N = 202) in the Upper East Region of Ghana, who had previously tested either positive (N = 446) or negative (N = 96) for FTS-CFA, participated in the study. Two follow-up visits were conducted; 1-4 years (follow-up-1) and 2-5 years (follow-up-2) after the baseline visit. Of the 446 FTS-CFA positives, 175 (39.2%) did not receive additional MDA (ivermectin/Albendazole) after the baseline visit. Overall, from the two follow-up visits, 159/175 (90.9%) FTS-CFA+ participants who did not receive any additional Ivermectin/Albendazole and 226 out of the 271 (83.4%) with additional MDA treatment became CFA negative. A total of 120 randomly selected baseline FTS-CFA+ samples were tested with Og4C3 TropBio ELISA and only 44/120 (36.7%) were found positive. Of these 44 participants, 12 (27.3%) completely became CFA negative and an additional 18 (40.9%) had reduced antigen levels during the follow-up. Likewise, all three previously/baseline microfilariae positive persons had become amicrofilaremic. In the present work, it has been shown that >90% of the previous CFA positive individuals seroreverted in 1 to 5 years post-baseline without additional MDA. The FTS is a more sensitive diagnostic tool that plausibly detects residual CFA in blood. The impact and influence of time as compared to additional ivermectin/Albendazole intake, on CFA seroreversion in this study was significant (p < 0.001).